SCHEMBL4284588

SCHEMBL4284588

COc1ccc(-c2nc(CC(C)(C)C(=O)c3ncccc3C)co2)cc1OC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
S1PR5 Q9H228 1/20 0.38
BRD4 O60885 1/20 0.36
BRPF1 P55201 1/20 0.36
SYK P43405 4/20 0.35
MTOR P42345 1/20 0.35
MKNK2 Q9HBH9 2/20 0.35
MKNK1 Q9BUB5 1/20 0.35
PTGS2 P35354 1/20 0.35
PDE4B Q07343 1/20 0.34
MAPK1 P28482 2/20 0.34
CDC7 O00311 1/20 0.34
PLK4 O00444 1/20 0.34
DYRK3 O43781 1/20 0.34
ROCK2 O75116 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
CDK1 P06493 1/20 0.34
CSF1R P07333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4276698 0.85 S1PR1 (0.42) S1PR1S1PR3S1PR5BRD4BRPF1
SCHEMBL4276096 0.84 GSK3B (0.42) S1PR1S1PR3S1PR5BRD4BRPF1
SCHEMBL4277053 0.81 LCLAT1 (0.36) SYKMKNK2PDE4BMAPK1CDC7
SCHEMBL20780184 0.78 SMN1; SMN2 (0.38) S1PR1S1PR3MAPK1LMNASMN1; SMN2
SCHEMBL4278473 0.78 S1PR1 (0.36) S1PR1S1PR3S1PR5PDE4BMAPK1
SCHEMBL4552121 0.78 SMN1; SMN2 (0.35) SYKMTORMKNK2PDE4BMAPK1
SCHEMBL4276856 0.78 PDE4B (0.35) S1PR1S1PR3S1PR5PTGS2PDE4B
SCHEMBL13701432 0.77 MAPT (0.39) PTGS2MAPK1THRBLMNAHTT
SCHEMBL4277707 0.77 S1PR1 (0.37) S1PR1S1PR3S1PR5PDE4BPPARG
SCHEMBL4271374 0.77 S1PR1 (0.37) S1PR1S1PR3S1PR5PDE4BPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 US disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
EP-1954684-B1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2014-05-07 EP disclosed
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-04-10 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
WO-2007058338-A9 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2007-11-01 WO disclosed
WO-2007058338-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B S1PR1 2919/4885S1PR3 3227/4885S1PR5 2210/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 902/4885S1PR3 1109/4885S1PR5 1527/4885
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.